NKE vs PFE: Which Is the Better Buy?
Side-by-side comparison of NIKE, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
NIKE, Inc. · Consumer Cyclical
$35.78
+9.9% upside to fair value
Med Conviction
Grade C
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NKE |
PFE |
| Current Price |
$35.78 |
$27.64 |
| Fair Value Estimate |
$39.33 |
$30.94 |
| Upside to Fair Value |
+9.9%
|
+12.0%
|
| Market Cap |
$53.0B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
12.0x
|
17.4x
|
| Price / Sales |
1.1x
|
2.5x
|
| Price / FCF |
24.3x
|
14.3x
|
| Revenue Growth YoY |
-1.1%
|
+2.6%
|
| Gross Margin |
42.9%
|
71.3%
|
| Operating Margin |
8.2%
|
25.1%
|
| Return on Equity |
22.0%
|
4.9%
|
| Dividend Yield |
4.58% |
6.22% |
| FCF Yield |
4.12%
|
6.97%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
NIKE designs, markets and distributes athletic footwear, apparel and equipment through the Nike, Jordan and Converse brands, supported by global athlete marketing, valuable intellectual property and a broad wholesale and owned-digital network. Business quality is medium: its brand moat and 22.0% ROE remain meaningful, but the moat is narrowing amid intense competition, weak direct sales and uneve…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
NKE |
PFE |
| Zone Low |
$29.50 |
$23.21 |
| Zone High |
$33.43 |
$26.30 |
| In Buy Zone? |
No
|
No
|